Shanghai Shyndec Pharmaceutical Past Earnings Performance
Past criteria checks 5/6
Shanghai Shyndec Pharmaceutical has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 1.2% per year. Shanghai Shyndec Pharmaceutical's return on equity is 7.6%, and it has net margins of 7.2%.
Key information
0.3%
Earnings growth rate
-2.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 1.2% |
| Return on equity | 7.6% |
| Net Margin | 7.2% |
| Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Shyndec Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 11,776 | 844 | 2,628 | 573 |
| 31 Dec 23 | 12,070 | 692 | 2,888 | 562 |
| 30 Sep 23 | 12,402 | 765 | 2,844 | 534 |
| 30 Jun 23 | 13,017 | 748 | 3,115 | 522 |
| 31 Mar 23 | 13,132 | 729 | 3,263 | 511 |
| 31 Dec 22 | 12,959 | 628 | 3,397 | 517 |
| 30 Sep 22 | 12,954 | 363 | 3,689 | 559 |
| 30 Jun 22 | 12,700 | 367 | 3,872 | 579 |
| 31 Mar 22 | 13,260 | 425 | 4,012 | 576 |
| 31 Dec 21 | 13,945 | 568 | 4,245 | 585 |
| 30 Sep 21 | 13,903 | 649 | 4,427 | 571 |
| 30 Jun 21 | 13,977 | 748 | 4,333 | 544 |
| 31 Mar 21 | 13,182 | 734 | 4,237 | 542 |
| 31 Dec 20 | 12,556 | 649 | 4,075 | 494 |
| 30 Sep 20 | 12,538 | 713 | 3,932 | 459 |
| 30 Jun 20 | 12,156 | 611 | 4,044 | 437 |
| 31 Mar 20 | 12,328 | 607 | 4,200 | 419 |
| 31 Dec 19 | 12,199 | 656 | 4,275 | 413 |
| 30 Sep 19 | 11,860 | 703 | 4,438 | 368 |
| 30 Jun 19 | 11,723 | 667 | 4,331 | 365 |
| 31 Mar 19 | 11,386 | 717 | 4,131 | 361 |
| 31 Dec 18 | 11,321 | 706 | 3,935 | 371 |
| 30 Sep 18 | 10,416 | 647 | 3,605 | 372 |
| 30 Jun 18 | 9,791 | 569 | 3,019 | 491 |
| 31 Mar 18 | 9,260 | 530 | 2,588 | 398 |
| 31 Dec 17 | 8,518 | 516 | 2,106 | 316 |
| 30 Sep 17 | 9,086 | 539 | 1,904 | 211 |
| 30 Jun 17 | 9,124 | 544 | 1,986 | 0 |
| 31 Mar 17 | 9,324 | 534 | 1,959 | 0 |
| 31 Dec 16 | 9,126 | 477 | 1,923 | 0 |
| 30 Sep 16 | 13,514 | 773 | 2,361 | 0 |
| 30 Jun 16 | 12,126 | 697 | 2,159 | 0 |
| 31 Mar 16 | 10,388 | 580 | 1,946 | 0 |
| 31 Dec 15 | 8,988 | 530 | 1,704 | 0 |
| 30 Sep 15 | 2,829 | 206 | 937 | 0 |
| 30 Jun 15 | 2,820 | 211 | 913 | 0 |
| 31 Mar 15 | 2,882 | 203 | 930 | 0 |
| 31 Dec 14 | 2,749 | 190 | 922 | 0 |
| 30 Sep 14 | 2,492 | 169 | 852 | 0 |
| 30 Jun 14 | 2,442 | 159 | 806 | 0 |
| 31 Mar 14 | 2,317 | 137 | 782 | 0 |
| 31 Dec 13 | 2,350 | 133 | 740 | 0 |
| 30 Sep 13 | 2,481 | 142 | 696 | 0 |
Quality Earnings: 600420 has high quality earnings.
Growing Profit Margin: 600420's current net profit margins (7.2%) are higher than last year (5.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600420's earnings have grown by 0.3% per year over the past 5 years.
Accelerating Growth: 600420's earnings growth over the past year (15.7%) exceeds its 5-year average (0.3% per year).
Earnings vs Industry: 600420 earnings growth over the past year (15.7%) exceeded the Pharmaceuticals industry -0.8%.
Return on Equity
High ROE: 600420's Return on Equity (7.6%) is considered low.